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ABSTRACT
In this study the role of cytochrome P450 2D (CYP2D) in the
pharmacokinetic/pharmacodynamic relationship of ()-tram-
adol [()-T] has been explored in rats. Male Wistar rats were
infused with ()-T in the absence of and during pretreatment
with a reversible CYP2D inhibitor quinine (Q), determining
plasma concentrations of Q, ()-T, and ()-O-demethyltram-
adol [()-M1], and measuring antinociception. Pharmacokinet-
ics of ()-M1, but not ()-T, was affected by Q pretreatment:
early after the start of ()-T infusion, levels of ()-M1 were
significantly lower (P  0.05). However, at later times during Q
infusion those levels increased continuously, exceeding the
values found in animals that did not receive the inhibitor. These
results suggest that CYP2D is involved in the formation and
elimination of ()-M1. In fact, results from another experiment
where ()-M1 was given in the presence and in absence of Q
showed that ()-M1 elimination clearance (CLME0) was signifi-
cantly lower (P 0.05) in animals receiving Q. Inhibition of both
()-M1 formation clearance (CLM10) and CLME0 were modeled
by an inhibitory EMAX model, and the estimates (relative stan-
dard error) of the maximum degree of inhibition (EMAX) and IC50,
plasma concentration of Q eliciting half of EMAX for CLM10 and
CLME0, were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml,
respectively. The modeling of the time course of antinocicep-
tion showed that the contribution of ()-T was negligible and
()-M1 was responsible for the observed effects, which depend
linearly on ()-M1 effect site concentrations. Therefore, the
CYP2D activity is a major determinant of the antinociception
elicited after ()-T administration.
Tramadol (T) is a safe and effective analgesic used during
the last two decades in the treatment of several types of pain
(Rhoda et al., 1993; Raffa et al., 1995). Despite its long-term
use, the understanding and prediction of the time course of
its pharmacological effects are still hampered by the pres-
ence of active metabolites and the coexistence of opioid and
nonopioid mechanisms. In fact, T is administered as a race-
mic mixture of two enantiomers, ()-T and ()-T, which are
metabolized in the liver forming, among others, the two main
active metabolites ()-O-demethyltramadol [()-M1] and
()-O-demethyltramadol [()-M1], respectively. Data from
literature suggest that ()-enantiomers show opioid proper-
ties, while ()-enantiomers are able to inhibit the uptake of
norepinephrine. This duality of action makes T an atypical
opioid (Raffa et al., 1992; Raffa and Friderichs, 1996).
Recently the antinociceptive properties of the two active
metabolites of T, ()-M1 and ()-M1, have been evaluated in
the pharmacokinetic/pharmacodynamic (pk/pd) perspective
in the rat. The results showed that ()-M1, in accord with its
-opioid receptor agonist properties (Lai et al., 1996), was
able to produce maximum antinociception in the tail-flick
test; however, when ()-M1, a monoamine re-uptake inhibi-
tor (Frink et al., 1996), was given alone, no significant effects
were found (Valle et al., 2000). However, Garrido et al., 2000
showed that in the presence of ()-M1, ()-M1 significantly
contributed to the antinociception elicited by the opioid, and
this contribution could be well described by a mechanism-
based pk/pd model incorporating the known pharmacological
properties of the two metabolite enantiomers.
The relative role of the enantiomers of T and M1 in anal-
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gesia after T administration is an issue that still has to be
addressed properly for at least two main reasons: first, data
from the literature suggest that ()-M1 is the main agent
responsible for T effects (Poulsen et al., 1996), and second,
the enzyme CYP2D6 is involved in M1 formation (Paar et al.,
1992, 1997). Taking into account the fact that this enzyme is
polymorphically expressed (Bertilsson et al., 1992) and even-
tually can be inhibited (Abdel-Rahman et al., 1999; Brynne et
al., 1999), situations where the CYP2D6 activity is decreased
are likely to occur, and therefore the relationship between
the degree of enzyme activity and analgesic response needs to
be established. In addition, to our knowledge the impact of
alterations in CYP2D6 activity on M1 elimination has not
been reported.
On the basis of these considerations, to gain a deeper
understanding of the kinetics of the in vivo T effects, the goal
of the present study was to investigate the impact of altered
CYP2D activity on the pharmacokinetics (pk) of ()-T and
()-M1, and on the time course of response, quantifying the
contribution of the parent drug and metabolite to the antino-
ciceptive effects. To achieve these goals, ()-T and ()-M1
were given to rats in the absence and presence of quinine (Q),
a potent reversible inhibitor of the CYP2D cluster in the rat
(Kobayashi et al., 1989).
Materials and Methods
Chemicals
()-T and ()-M1 were obtained from Gru¨nenthal GmbH (Aachen,
Germany). Q, quinidine, and ketamine HCl were purchased from
Sigma-Aldrich (Madrid, Spain). Anesthetics, xylazine (Xilagesic, 2%)
and ketamine (Ketolar, 50 mg) were purchase from Calier SA (Bar-
celona, Spain), and Parke-Davis (Barcelona, Spain), respectively. All
the reagents and solvents were of analytical grade.
Animals
Male Wistar rats weighing 220 to 260 g were kept under labora-
tory standard conditions on a 12-h light/dark cycle with light from
8:00 AM to 8:00 PM in a temperature (22°C)-controlled room, and
were acclimatized for a minimum of 2 days before experiments were
performed. They were housed in individual cages after the surgical
procedures, with free access to water. Food (standard laboratory rat,
mouse, and hamster diets; Panlab SL, Barcelona, Spain) was with-
held for 12 h before the start of experiments. The protocol of the
studies was approved by the Animal Experimentation Committee of
the University of Navarra.
Surgical Procedure and Drug Administration
Twenty-four hours before the start of the experiments three per-
manent cannulas were implanted under ketamine/xylazine (75:25
mg/kg i.p.) anesthesia. One in the left femoral artery (0.3 mm i.d., 20
cm long; Vygon, Ecouen, France) was used for blood sample collec-
tion, one in the internal right jugular vein for saline or Q infusion,
and the last one in the external right jugular vein for ()-T or ()-M1
administration (0.5 mm i.d., 10 cm long; Vygon). All cannulas were
filled with a heparinized physiological saline solution (20 IU/ml) to
prevent clotting and were tunneled under the skin and externalized
on the dorsal surface of the neck.
Fresh stock solutions containing ()-T, ()-M1, or Q in concentra-
tions of 21, 3.75, and 7 mg/ml, respectively, were prepared just before
the start of each experiment. ()-T and ()-M1 were dissolved in
physiological saline, and Q in dimethylsulfoxide and further diluted
with physiological saline 20:80 (v/v). Drug solutions were adminis-
tered using a dual syringe pump (model 33; Harvard apparatus;
Panlab SL). The total volume administered did not exceed 1.5 ml
regardless of the duration of the infusions.
Study Design
The study is divided into two experiments. In experiments I and II
()-T or ()-M1 were the antinociceptive drugs given, respectively.
Experiment I. Twenty-four male Wistar rats were randomly
allocated to four (n  6) different groups. Group I, used as a control,
received saline as an i.v. infusion for 80 min. In the rest of the
groups, animals received a 10-min i.v. infusion of 25 to 32 mg/kg to
()-T. Ten minutes before ()-T administration, saline was infused
for 40 min in group II, and in groups III and IV, Q was given
according to the following infusion scheme: 4 mg/kg were injected as
an i.v. bolus followed by a 40 mg/kg dose infused in 40 (group III) or
80 (group IV) min.
Experiment II. Twelve male Wistar rats were divided at random
into two (n  6) groups. All animals received 3 mg/kg of ()-M1
infused over 15 min. Ten min before ()-M1 administration, saline
(group V) or Q (group VI) were infused for 40 min. Group VI received
Q as in group III. Figure 1 shows the experimental drug adminis-
tration design used in the study.
In groups II–VI, to determine the pk of ()-T, ()-M1, and Q and
to measure respiratory effects, several (7–10) blood samples (100–
125 l) were withdrawn at fixed intervals over the time course of the
study. The volume of blood withdrawn did not exceed 10% of the total
blood volume. Blood samples were immediately centrifuged at 2500
rpm for 15 min and the plasma was stored at 20°C until HPLC
analysis (see below).
In groups I–VI and in the pilot study receiving Q in a five-min i.v.
infusion, antinociception was evaluated from the beginning of Q or
saline administration to at least 3 h after the start of the experi-
ments using the radiant-heat tail-flick technique (D’Amour and
Smith, 1941). Antinociception was expressed as tail-flick latency (s)
measured automatically with a Letica analgesimeter (Letica, Panlab
SL). Baseline latencies were between 2.5 and 3.5 s; animals with
higher baseline latencies were excluded from the study. A maximum
cutoff of 10 s was fixed to prevent tissue damage. Respiratory effects
were evaluated quantifying the arterial levels of pH, pCO2, and pO2
using a portable clinical analyzer (i-STAT portable clinical analyzer,
Abbott, Barcelona, Spain).
Drug Assays
Q. Plasma concentrations of Q were determined by a sensitive
HPLC assay. Forty l of plasma were added to 110 l of an NH3
(20%) solution containing the internal standard quinidine HCl (0.2
Fig. 1. Experimental design for saline, quinine, ()-T, and ()-M1 ad-
ministration in the different groups of animals used in the study. The
length of the infusions is represented by the solid bars.
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g/ml). This mixture was shaken and mixed with 1 ml of a hexane-
ethyl acetate solution (9:1; v/v). The organic layer was separated
after shaking the mixture in vortex for 1 min and centrifuging at
4000 rpm for 6 min. This organic phase was evaporated to dryness at
35°C under reduced pressure (rotatory evaporator, model 43220000;
Labconco, Kansas City, MO). The solid residue was reconstituted
with 125 l of 0.9% NaCl solution (pH  4.5) and a 100-l aliquot
was injected into the HPLC system.
The chromatographic system consisted of a Hewlett Packard
HPLC HP 1100 equipped with a quaternary pump, autosampler, and
fluorescence detector. The excitation and emission  were 346 and
442 nm, respectively.
The analytical separation was performed at 35°C by an Ultrabase
C18 column (250  4.6-mm i.d.) packed with cellulose Tris (3,5-
dimethylphenylcarbamate) coated in silica (10 m) (Scharlau, Bar-
celona, Spain), preceded by a C18 guard column (TR-C-160K1,
Tracer, Barcelona, Spain). The mobile phase consisting of H2O, ace-
tonitrile, and a 10% acetic acid solution (10:14:76; v/v/v), was filtered
through a 0.45-m pore size membrane filter. The flow rate was 1
ml/min.
Retention times of 10 and 12 min were found for quinidine and Q,
respectively. The accuracy of the assay was 11%. The intra and
interassay coefficients of variation were less than 7%. The method
showed linearity within the concentration range studied and the
limit of quantification was considered 4 ng/ml.
()-T and ()-M1. Plasma concentrations of ()-T and ()-M1
were determined by a sensitive and stereoselective HPLC assay
(Campanero et al., 1999). Plasma samples (50 l) were transferred
into glass tubes mixed with 50 l of internal standard (ketamine
HCl), 1 ml of Tris buffer (pH 9.5, 0.05 M), and 6 ml of tert-butyl
methylether. The mixture was shaken for 1 min and the organic
layer was separated after centrifugation at 3500 rpm for 10 min. The
organic phase was evaporated to dryness at 40°C under reduced
pressure (rotatory evaporator, model 43220000; Labconco). The res-
idue was reconstituted in 250 l of mobile phase and mixed in vortex
for 1 min. A 100 l aliquot was then injected into the HPLC system.
The chromatographic system consisted of a Hewlett Packard
HPLC HP 1100 equipped with a quaternary pump, autosampler, and
fluorescence detector. The excitation and emission  were 199 and
301 nm, respectively.
The analytical separation was performed at 20  3°C by a Chiral-
cel OD-R column (250  4.6-mm i.d.) packed with cellulose Tris
(3,5-dimethylphenylcarbamate) coated in silica (10 m) (Daicel
Chemical Industries, Tokyo, Japan), preceded by a reversed phase,
100  4-mm end-capped column packed with 3 m of C8 silica
reversed phase particles (Hypersil BDS C18; Hewlett Packard). A
guard column (4  4 mm) packed with Lichrosphere 100 DIOL (5
m) from Merck (Barcelona, Spain) was connected to the column
system. The mobile phase consisting of acetonitrile plus 0.05 M
sodium dihydrogen phosphate, thiethylamine (0.09 M), and sodium
perchlorate (0.2 M), adjusted to pH 5.5 with hydrochloric acid 2 M (20
acetonitrile/80 buffer, pH 5.5), was filtered through a 0.45-m pore
size membrane filter. The flow rate was 0.6 ml/min.
Retention times of 40 and 15 min were found for ()-T and ()-M1,
respectively. The accuracy of the assay was 15%. The intra and
interassay coefficients of variation were less than 5%. The method
was linear within the concentration range studied and the limit of
quantification was considered 10 ng/ml for both compounds.
Data Analysis. All analyses were performed with NONMEM,
version V, level 1.1 (Beal and Sheiner, 1992) using the population
approach that allows the estimation of the fixed (typical population)
and random (interanimal and residual variability) parameters. In-
teranimal variability (IAV) was modeled exponentially and ex-
pressed as coefficient of variation. Differences between the observed
drug plasma concentrations and model predictions were modeled
with proportional error models. To describe the time course of an-
tinociception a survival analysis was performed (see below) and
therefore, a residual error model does not apply.
Model selection was based on a number of criteria, such as the
exploratory analysis of the goodness-of-fit plots, the estimates, and
the precision (represented by the relative standard error [RSE] com-
puted as the ratio between the standard error and the parameter
estimate) of the fixed and random parameters, and the minimum
value of the objective function (OBJ) provided by NONMEM. The
difference in the OBJ between two hierarchical models was com-
pared with a 2 distribution in which a difference of 6.63 points is
significant at the 1% level.
Data from experiments I and II were fitted separately in three
steps: step 1, pk analysis of Q in plasma; step 2, the model selected
in step 1 and its parameter estimates were used to characterize the
Q versus ()-T and Q versus ()-M1 interactions; step 3, using the
models selected during steps 1 and 2 and its parameter estimates,
the time course of antinociceptive response was modeled.
Pk Modeling. Step 1: kinetics of Q in plasma was described using
standard compartmental models; step 2: Fig. 2 shows the model used
to describe the plasma versus time profiles of ()-T and ()-M1
obtained from experiment I in the presence and in absence of Q.
Formation of ()-M1 was described by a first-order process that was
assumed to be reversibly inhibited by the presence of Q:
CLM1  CLM10 1 EMAX CQCQ IC50
Where CLM1 is the ()-M1 formation plasma clearance at any time
of the experiment, CLM10 is the ()-M1 formation plasma clearance
in absence of Q, EMAX is the maximum Q-induced decrease in CLM10,
and IC50 is the plasma concentration of Q (CQ) eliciting half of EMAX.
The estimate of EMAX was constrained between 0 and 1. During the
analysis the apparent volumes of distribution of the central compart-
ment for ()-T and ()-M1 were assumed to be the same.
Results from experiment II (see below) showed that elimination of
()-M1 was also impaired in the presence of Q, thus the same
inhibitory model was used to describe the decrease in the plasma
()-M1 clearance (CLME0). During the model-building process differ-
ent estimates of EMAX and IC50 for the case of CLM10 and CLME0
inhibition were tested. In addition, the presence of more than one
route of elimination for ()-T and ()-M1 was also evaluated. A
detailed description of the key models explored during this step is
presented Appendix I.
Pd Modeling. From the total of effect measurements in both
experiments, 30% were censored (i.e., recorded as 10 s). To integrate
appropriately the censored information in the analysis the time-to-
event approach was used (Luks et al., 1998) where the time at which
the animal responds to the nociceptive stimuli is given by a proba-
bility density distribution. In the present study, the Weibull distri-
bution (Klein and Moeschberger, 1997; Luks et al., 1998), which is
Fig. 2. Schematic representation of the model selected to describe the
pharmacokinetic data from experiment I.
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characterized by the median time to response (M) and the shape of
the probability distribution (Z), was used. M was expressed as fol-
lows: E0  f(Ce), where E0 represents the baseline latency, f is the
pharmacodynamic model (i.e., linear, EMAX, or sigmoidal EMAX), and
Ce corresponds to effect site concentrations (Sheiner et al., 1979) of
()-T or ()-M1. An eventual interaction between the parent drug
and its metabolite was also evaluated; in this case the general model
E0  f(Ce ()-M1, Ce ()-T) was applied, f being an interaction (i.e.,
additive, non, or competitive) model. The value of Z was assumed to
be independent of drug concentration. Appendix II describes the key
models fitted during this step of the analysis.
The likelihood of each noncensored time to response (i.e., 10 s) is
proportional to the density evaluated at that observed time to re-
sponse; in the case of a censored observation (i.e., 10 s), the likeli-
hood is proportional to the area under the Weibull density curve from
10 s to  (survival). The expressions corresponding to density (D) and
survival (S) are:
D  Z  ObservationM 
Z
 ln(2)
S
Observation
S  0.5ObservationM Z
Where observation refers to observed response latency.
Statistical Analysis. To evaluate differences within each group
in respiratory parameters with respect to baseline, a paired Stu-
dent’s t test was used. Differences between groups in latencies and
respiratory parameters at baseline were evaluated with an analysis
of variance test followed by the F test. A probability level of P  0.05
was considered to be statistically significant. Raw data are expressed
in the text as mean (standard deviation [S.D.]) and model-derived
parameters as their estimate (RSE).
Results
Animals in the control and in the Q pilot study groups did
not show significant antinociception or changes in the respi-
ratory parameters during and after the saline or Q infusion,
respectively (P  0.05). Baseline latency and respiratory
parameter values did not differ significantly (P  0.05)
among all groups of animals. Mean (S.D.) baseline latency
and respiratory parameter values were 2.8 (0.1) s, 7.51 (0.03;
pH), 80.2 (6.3; pO2), and 35.1 (5.2; pCO2), respectively.
Experiment I
Step I: pk Modeling of Q. Figure 3 shows the mean Q
observed plasma concentrations versus time profiles in
groups III and IV. Maximum Q concentrations in plasma
were achieved at the end of the infusion and showed mean
(S.D.) values of 7150 (1214), group III, and 5137 (1387) ng/ml,
group IV. The kinetics of Q in plasma was best described with
a two-compartment model with interanimal variability asso-
ciated to plasma clearance (CL), and apparent volumes of
distribution of the central (V) and peripheral (VT) compart-
ments. Table 1 lists the estimates of the pk parameters, and
typical population predictions are also shown in Fig. 3.
Step II: Simultaneous pk Modeling of ()-T and ()-
M1. The six panels in Fig. 4 show the mean observed plasma
concentrations versus time profiles of ()-T and ()-M1. In
group II (upper and lower left panels) ()-M1 formation was
very rapid; at the time the infusion of ()-T was stopped the
plasma ()-M1 concentrations reach the maximum with a
mean (S.D.) value of 772 (188) ng/ml. From the middle and
right panels in Fig. 4 it is apparent that the kinetics of ()-T
in plasma remained almost unaffected by the presence of Q;
on the contrary, the plasma versus time profiles of ()-M1
showed major changes. It is clear that, at least, at early times
after the start of ()-T infusion formation of ()-M1 is im-
paired. For example, mean (S.D.) observed ()-M1 levels 5
min after the start of the infusion were 411 (222), 88 (23), and
24 (1.5) ng/ml for groups II–IV, respectively. The correspond-
ing levels 10 min after the start of the infusion were 772
(188), 152 (51), and 113 (42) ng/ml for groups II–IV, respec-
tively. However, and despite the presence of Q in plasma (see
Fig. 3), levels of ()-M1 increased continuously, reaching a
maximum at 120 (group III) and 60 (group IV) min, respec-
tively. At these times and until end of the experiment,
()-M1 levels in groups III and IV were similar to or even
higher than in group II. On the basis of these observations, it
can be anticipated that a model considering only an effect of
Fig. 3. Plasma Q concentration versus time profiles. Symbols, mean raw
data: circles (G-III), triangles (G-IV). Lines represent typical model pre-
dictions: solid (G-III), dashed (G-IV). Vertical lines correspond to stan-
dard deviation.
TABLE 1
Pharmacokinetic parameters of Q in rats
Parameter Estimate (RSE) IAV (RSE)
V (l) 0.36 (0.14) 42 (0.55)
VT (l) 0.88 (0.18) 30 (0.53)
CLD (l/min) 0.051 (0.19) N.E.
CL (l/min) 0.024 (0.21) 72 (0.58)
V, apparent volume of distribution of the central compartment; VT, apparent
volume of distribution of the peripheral compartment; CLD, distribution clearance;
CL, elimination clearance; IAV, interanimal variability expressed as coefficient of
variation; RSE, relative standard error; N.E., not estimated.
TABLE 2
Quinine CYP2D inhibition and ()-T and ()-M1 pharmacokinetic
parameters in the rat
Parameter Estimate (RSE) IAV (RSE)
V (l) 0.055 (0.8) N.E.
VT (l) 0.88 (0.04) 14 (0.41)
CLD (l/min) 0.16 (0.15) N.E.
CLM10 (l/min) 0.0019 (0.43) N.E.
CLM2 (l/min) 0.0061 (0.12) 30 (0.19)
CLME0 (l/min) 0.018 (0.42) N.E.
EMAX 0.94 (0.04) N.E.
IC50_CLM10 (ng/ml) 97.2 (0.51) N.E.
IC50_CLME0 (ng/ml) 47.8 (0.42) N.E.
V, apparent volume of distribution of the central compartment; VT, apparent
volume of distribution of the peripheral compartment; CLD, distribution clearance;
CLM10 initial ()-M1 formation clearance; CLM2, plasma clearance representing
other routes of ()-T elimination; CLME0, initial apparent ()-M1 elimination clear-
ance; EMAX, maximum degree of inhibition in CLM10 and CLME0 that quinine is able
to induce; IC50_CLM10, and IC50_CLME0, plasma concentrations of quinine eliciting
half of EMAX on CLM10 and CLME0, respectively; IAV, interanimal variability ex-
pressed as coefficient of variation; RSE, relative standard error; N.E., not estimated.
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Q on CLM10 would not be enough to describe the data. The
dashed lines in Fig. 4 represent the predictions from such a
model [model 2 (Appendix I)] and clearly show the lack of fit,
evidencing the need for an extra effect of Q. Taking into
account the fact that Q was able to reduce ()-M1 elimina-
tion (see results from experiment II), a model including an
additional inhibitory effect of Q on CLME0 was fitted to the
data, resulting in a better fit (solid lines in Fig. 4 and model
7 (Appendix I)]. The difference in the OBJ value between the
two cited models was 102 points for one additional parameter
(P  0.001). Other features of the selected model are 1) the
two compartments describing ()-T disposition; 2) the pres-
ence of a second elimination pathway for ()-T; 3) the mono-
compartmental disposition properties of ()-M1; and 4) the
difference in the inhibitory potency of Q with respect to
CLM10 and CLME0, reflected in the estimates of the IC50
listed in Table 2. These features were selected on the basis of
the results from the model development process (see Appen-
dix I). The rest of the pk parameters of ()-T and ()-M1 are
also listed in Table 2.
Step III: pk/pd Modeling of the Antinociceptive Ef-
fects. Mean raw effect versus time data represented in Fig.
5 resembled the ()-M1 concentration versus time profiles
shown in Fig. 4, suggesting that ()-M1 plays a major role in
the observed antinociception. In fact, a difference in OBJ of
95 points was found between the models using ()-T [model
3 (Appendix II)] or ()-M1 [model 4 (Appendix II)] effect site
concentrations as the active compound. Results from models
describing the observed effects based on a pd interaction
between ()-T and ()-M1 [model 5 (Appendix II)] indicated
that the contribution of ()-T to antinociception was negligi-
ble. The final selected model linearly relates M with effect
site concentrations of ()-M1. More complex relationships
such EMAX [model 6 (Appendix II)] or sigmoidal (not shown)
did not significantly improve the fit (P  0.05). IAV variabil-
ity was estimated in baseline and in the slope parameter of
the linear model. Table 3 lists the estimates of the pd param-
eters and Fig. 5 shows also the typical model predicted an-
tinociception versus time profiles.
Experiment II
Step I: pk Modeling of Q. In this experiment individual
fitting was performed and then mean and standard deviation
of the parameters were computed (Steimer et al., 1984). This
procedure was carried out because the population analysis
with six rats did not provide adequate results. Q plasma
concentration versus time profiles obtained during this experi-
ment were similar to those obtained for group III. Mean (S.D.)
estimates of V, VT, distribution clearance (CLD), and CL were
0.25 (0.11) l, 0.93 (0.18) l, 0.078 (0.06) l/min, and 0.012 (0.003)
l/min, respectively; values close to the estimates found in exper-
iment I (see Table 1).
Fig. 4. Plasma ()-T (upper panels) or ()-M1 (lower panels) concentration versus time profiles. Group II, left panels (G-II), group III, middle panels
(G-III), and group IV, right panels (G-IV). Symbols represent mean raw data and vertical lines correspond to standard deviations. Lines show typical
predictions from the selected model (solid lines) and the model that did not include an inhibitory quinine effect on ()-M1 elimination (dashed lines).
TABLE 3
Pharmacokinetic/pharmacodynamic parameters of ()-M1 in the rat
Parameter Estimate (RSE) IAV (RSE)
E0 (s) 2.77 (0.04) 5 (0.25)
Slope (s  ml/ng) 0.0123 (0.11) 46 (0.36)
ke0 (l/min) 0.0665 (0.11) N.E.
Z 6.64 (0.075) N.E.
E0, baseline latency; slope, slope of the linear relationship between response and
effect site concentrations; ke0, first-order rate constant governing the distribution
from plasma to the effect site; Z, parameter representing the shape of the Weibull
distribution; IAV, interanimal variability expressed as coefficient of variation; RSE,
relative standard error; N.E., not estimated.
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Step II: pk Modeling of ()-M1. Figure 6 (left panel)
shows the mean observed plasma concentration versus time
profiles in groups V and VI, where it is clear that the pres-
ence of Q impaired ()-M1 elimination. Inhibitory effects of Q
were modeled as in the analysis of experiment I data. Esti-
mates (RSE) of EMAX and IC50 were 0.95 (0.18) and 83 (0.53)
ng/ml, respectively. When ()-M1 was infused in rats a two-
compartment model significantly improved the fit with re-
spect to the simpler one-compartment model (P  0.05).
Estimates (RSE) of V, VT, CLD, and CL were 0.32 (0.17) l,
0.96 (0.10) l, 0.08 (0.26) l/min, and 0.022 (0.13) l/min, respec-
tively. IAV (RSE) was estimated in V and CL with values of
41 (0.47)% and 80 (0.81)%, respectively. Effects of Q were also
evaluated in the rest of the pk parameters but no significance
(P 0.05) was found. Lines in Fig. 6 (left panel) represent the
adequacy of the selected model.
Step III: pk/pd Modeling of the Antinociceptive Ef-
fects. The right panel in Fig. 6 shows that antinociceptive
effects in group VI are maintained for a longer period of time
with respect to group V. This observation was expected, tak-
ing into account the difference in the ()-M1 plasma versus
time profiles seen in the left panel of Fig. 6. The model used
to describe the time course of response data was similar to
the one fitted to the experiment I data. Estimates (RSE) of
baseline, the slope of the linear effect versus effect site con-
centration relationship, ke0, the first-order rate constant gov-
erning drug distribution from plasma to the effect site, and Z
were 2.81 (0.02) s, 0.0214 (0.02) sml/ng, 0.0485 (0.14) l/min,
and 4.51 (0.15), respectively. IAV (RSE) was estimated in
baseline and slope with values of 6 (0.16)% and 24 (0.33)%,
respectively. Model estimates between both experiments
were also similar (see Table 3). At later times after the start
of the experiment in group VI the model provided typical
predictions higher than the median observed values, which
should not be interpreted totally as a lack of fit, since the use
of the time-to-event approach allows response predictions to
be higher than 10 s (cutoff time). To improve the overpredic-
tion of the observed data at 180 min different tolerance
models were fitted to the data (Gårdmark et al., 1999), but no
improvements were achieved.
Discussion
It has been suggested that in the analgesic response to T
several mechanisms of action can be involved, in addition to
the metabolite contribution (Raffa et al., 1995). Taking into
account this complex scenario, the current research repre-
sents the third of a series of studies with the goal of under-
standing and predicting the in vivo time course of T effects,
where the key parts of the system are treated separately. In
previous reports the in vivo characterization of ()-M1 and
()-M1 was carried out (Garrido et al., 2000; Valle et al.,
2000). Results showed that the pk/pd approach was suitable
to describe their in vivo effects reflecting their pd properties
studied previously in in vitro studies. However, to our knowl-
edge the respective contributions of T and M1 enantiomers to
the response has not been quantified. There are in vitro as
well as clinical data suggesting that ()-M1 plays an impor-
tant role. For example, it shows a moderate affinity for -opi-
oid receptors (Lai et al., 1996), and individuals with an im-
paired ()-M1 formation (poor metabolizers) showed a
decreased degree of analgesia after T administration
(Poulsen et al., 1996). Since ()-M1 formation in humans is
governed by the enzyme CYP2D6 (Paar et al., 1992, 1997),
the identification of factors affecting the CYP2D6 activity
Fig. 5. Time course of antinociception. Symbols, median raw data. Vertical lines represent the dispersion in the data and have a value equal to the standard
deviation of the mean. Lines show typical model predicted effect versus time profiles.
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and establishing the relationship between such activity and
analgesia are required to optimize the use of T.
In this study a pk/pd model was developed that allows us to
explore the impact of alterations in CYP2D cluster activity in
the time course of antinociception after ()-T administration
in rats. CYP2D1 activity in the rat has been used as a model
of CYP2D6 activity in humans (Al-Dabbagh et al., 1981);
however, there are data suggesting that in the rat, debriso-
quine hydroxylation is not restricted to CYP2D1 (Kahn et al.,
1985). For this reason the general notation of CYP2D has
been used in the text.
Alteration of CYP2D activity was achieved infusing Q, a
compound that has been reported to be a potent reversible
CYP2D inhibitor in the rat (Kobayashi et al., 1989; Tomkins
et al., 1997). In a pilot study carried out in rats receiving Q in
a short i.v. infusion (data not shown), Q did not elicit signif-
icant (P  0.05) antinociception in the tail-flick test, and
showed a short elimination half-life; thus considering the
reversible nature of the interaction, in experiments I and II Q
was infused for 40 or 80 min to ensure CYP2D inhibition
during and after ()-T administration. Q administered at
doses of 20 mg/kg was able to suppress CYP2D activity in the
rat (Tomkins et al., 1997) and 2.4 M (867 ng/ml) corre-
sponds to its IC50 value for the inhibition of the debrisoquine
4-hydroxylase activity in rat liver microsomes (Kobayashi et
al., 1989). In our study a bolus i.v. dose of 4 mg/kg followed by
40 mg/kg given in 40- or 80-min infusions showed, at the end
of the infusions, mean Q plasma concentrations of 7150 or
5135 ng/ml, which, on the basis of literature data, would
elicit maximum CYP2D inhibition. There are potential draw-
backs in the use of Q to study the effects of a drug such as T,
since it is known that this compound induces the release and
inhibits the reuptake of monoamines in rat brain tissue
(Clement et al., 1998) and a contribution of this mechanism
to the -opioid analgesia has been reported and modeled
(Garrido et al., 2000). However, the estimates of the potency
of Q for its monoamine uptake and release effects are higher
compared with the plasma Q concentration achieved in our
study (Clement et al., 1998).
The plasma ()-T concentration versus time profiles was
not apparently modified in the presence of Q, despite the
Q-induced decrease in CLM10. This observation is compatible
with the complex metabolism of T shown in humans where
several metabolites have been identified (Lintz et al., 1981),
and with the fact that the estimate of CLM10 (0.0019 l/min)
represents only 23% of the total ()-T elimination clearance
(0.008 l/min). However, plasma ()-M1 concentration versus
time profiles showed a marked alteration; this finding rein-
forces the need for a simultaneous determination of T and M1
in pk and pk/pd studies with T. Our results confirm that
formation of ()-M1 is controlled by CYP2D activity in the
rat. To quantify the extent of the Q-induced inhibition, mod-
eling the data was required. In a first step a model incorpo-
rating the effects of Q on CLM10 was fitted to the data
(dashed lines in Fig. 4); the resulted misfit justified the
search for a more elaborate model. The model selected in-
cludes Q inhibition in CLM10 and CLME0. With this approach
predictions were adequate to describe the data (solid line in
Fig. 4). Although the inhibition of CLM10 was supported by
literature data, the effect of CLME0 was unexpected. There-
fore, a second experiment was performed with the goal of
exploring the possible effects of Q on ()-M1 elimination. The
findings were clear and the observations confirmed the mod-
eling results from experiment I. The estimate obtained for
EMAX indicates that Q cannot completely inhibit the CYP2D
activity, a result that is in accordance with findings from in
vitro data (Kobayashi et al., 1989). The estimates of IC50
obtained for CLM10 (97.2 ng/ml) and CLME0 [47.8 (experiment
I) and 83 (experiment II) ng/ml] are of the same order and low
compared with the concentrations of Q achieved in plasma
(which indicates that little information about the lower por-
tion of the inhibition versus concentration curves has been
gained). Therefore, it is likely that Q could induce the inhi-
bition of the formation and elimination of ()-M1 with the
same potency.
Pk/pd modeling showed that the contribution of ()-T to
antinociception was negligible and antinociception is caused
by the presence of ()-M1, which is in agreement with the
very low affinity of the parent drug for the -opioid receptors
(Raffa et al., 1992; Frink et al., 1996). This finding helps to
complete the complex picture of the time course of T effects.
Our pk/pd studies have demonstrated that ()-M1, but not
()-T and ()-M1, can elicit maximum antinociception in the
tail-flick test. In addition, ()-M1 at high concentrations is
able to contribute to the ()-M1 antinociceptive effects. The
modeling of the possible interaction between ()-T and
()-M1 is still missing and would require a more appropriate
animal model for antinociception to explore the nonopioid
component in the response (Le Bars et al., 2001). Due to the
presence of censored observations, during the pk/pd modeling
Fig. 6. Plasma ()-M1 concentration (left panel) and effect (right panel) versus time profiles in groups V and VI. Symbols represent mean (G-V) or
median (G-VI) raw data. Vertical lines in group V represent standard deviations; in the case of group VI, vertical lines show the dispersion in the data
and have a value equal to the standard deviation of the mean. Lines show typical model predictions.
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the time-to-event approach was used, which allows the cor-
rect use of the censored data. Nevertheless, the resulting
selected models and estimates of model parameters are sim-
ilar to those reported previously (Garrido et al., 2000; Valle et
al., 2000).
Since ()-M1 disposition depends only on CYP2D activity
and response is only mediated by ()-M1 in the effect site,
CYP2D activity plays a major role in response. To further ex-
plore the impact of a decrease in CYP2D activity on drug effects
the following simulation exercise was performed: the response
versus time profiles were generated in cases of complete (100%),
50, 25, 10, or 5% inhibition of the initial CYP2D activity, as-
suming 1) only ()-M1 formation is affected; and 2) both forma-
tion and elimination of ()-M1 are affected. Figure 7 shows the
results from the simulations. It is clear that in the case of an
inhibition in both formation and elimination of ()-M1 the
impact of the altered CYP2D activity is mitigated, principally
affecting the onset time of antinociception, resembling the ob-
servations obtained in the present study.
As a last comment, it is recognized that it would have been
more elegant to fit all data from experiments I and II simul-
taneously. In fact, this was tried but ()-M1 plasma versus
time profiles from groups II and V were not described ade-
quately, even though several models were explored. This
result could be interpreted as an interaction between the
parent drug and the metabolite at the pk level. However, the
data from this study did not support the interaction models.
Therefore, further experiments addressed to explore this is-
sue should be designed.
In conclusion, CYP2D activity plays a crucial role in the
antinociception after ()-T administration since it controls
the formation and elimination of the metabolite ()-M1,
which is the active compound. Results were obtained by
modifying CYPD2D activity in the rat by administering its
reversible inhibitor Q. One of the main findings of the study
is that CYP2D appears also to be involved in ()-M1 elimi-
nation.
Fig. 7. Simulated effect versus time profiles in the presence of a constant 0, 50, 75, 90, and 95% reduction in CLM10 (left panel) and in both CLM10 and CLME0 (right
panel).
APPENDIX I
Results from the key models explored during the development of the pharmacokinetic model in the experiment I
Results listed show that the presence of Q has a significant effect on both CLM1 and CLME (models 2, 3, and 4; P  0.001). The inclusion of another elimination route for the
case of ()-T was highly significant (model 5; P  0.001), and model 6 shows that such additional route was not significantly affected by Q (P  0.05). Model 7, which
corresponds to the selected model, indicates that the estimation of different IC50 for the effect of Q on CLM1 and CLME improved the fit significantly (P  0.01).
Model Model Structure OBJ 	OBJ
1 ()-T: Two compartments; CLM2; CLM1 3501
()-M1: One compartment; CLME
2 ()-T: Two compartments; CLM2; CLM1 
 I(Q) 3066 435.0
a
()-M1: One compartment; CLME
3 ()-T: Two compartments; CLM2; CLM1 3280 221.0
a
()-M1: One compartment; CLME 
 I(Q)
4 ()-T: Two compartments; CLM2; CLM1 
 I(Q) 2973 93.0
b
()-M1: One compartment; CLME 
 I(Q)
5 ()-T: Two compartments; CLM2  0; CLM1 
 I(Q) 3058 85
c
()-M1: One compartment; CLME 
 I(Q)
6 ()-T: Two compartments; CLM2 
 I(Q); CLM1 
 I(Q) 2973 0.0
c
()-M1: One compartment; CLME 
 I(Q)
7 ()-T: Two compartments; CLM2; CLM1 
 I(Q, IC50_CLM1) 2964 9.0
c
()-M1: One compartment; CLME 
 I(Q, IC50_CLME)
()-T, ()-tramadol; ()-M1, ()-O-demethyltramadol; CLM1, ()-M1 formation plasma clearance; CLM2, clearance representing other routes of elimination; CLME,
()-M1 plasma clearance; Q, predicted quinine plasma concentrations; I0, inhibitory EMAX model; IC50, level of Q eliciting half of maximum CLM1 or CLME inhibition; OBJ,
minimum value of the objective function; 	OBJ, difference in OBJ.
a,b,c 	OBJ with respect to model 1, model 2, and model 4, respectively.
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APPENDIX II
Results from the key models explored during the development of the
pharmacokinetic/pharmacodynamic model in the experiment I
Results listed show that Ce_()-M1 (model 4) is a significant (P  0.001) better
predictor of the antinociceptive effects than plasma concentrations of ()-T, C_()-T,
(model 1), ()-M1, C_()-M1, (model 2), or Ce_()-T (model 3). In model 5, an interaction
between ()-T and ()-M1 was explored but the fit was not improved significantly
(P  0.05); the same results were found where the relationship between antinoci-
ception and Ce_()-M1 was modeled with an EMAX model (P  0.05).
Model Structure OBJ 	OBJ
1 Antinoception  lin (C_()-T) 1005
2 Antinociception  lin (C_()-M1) 937 68
a
3 Antinoception  lin (Ce_()-T) 809 128
b
4 Antinociception  lin (Ce_()-M1) 714 95
c
5 Antinociception  lin (Ce_()-M1, Ce_()-T) 714 0
d
6 Antinociception  EMAX (Ce_()-M1) 714 0
d
Lin 0, linear model; C_()-T, plasma ()-T concentrations; C_()-M1, plasma ()-M1
concentrations; Ce_()-T, effect site ()-T concentrations; Ce_()-M1, effect site ()-M1
concentrations; EMAX 0, EMAX model; OBJ, minimum value of the objective function;
	OBJ, difference in OBJ.
a,b,c,d 	OBJ with respect to model 1, model 2, model 3, and model 4, respectively.
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